Arrowhead adds newest facility to its Midwest hub in RNAi drug production push
Arrowhead Pharmaceuticals has purchased 13 acres of land in Wisconsin’s Verona Technology Park and will build a 140,000-square-foot drug manufacturing facility.
The company will spend between $200 million and $250 million to build out the facilities, and the site is expected to create another 250 jobs for the region. Construction starts in Q1. Arrowhead already has operations in Madison, WI, about 10 miles away.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.